Skip to main content
HCPCS J7682 · Level II · Part B drug

HCPCS J7682: Tobramycin, inhalation solution, fda-approved final product, non-compounded,

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: ASP payment limits October 2026 (effective October 1, 2026); MUE and NCCI edits 2026 Q4 (effective October 1, 2026); OPPS Addendum B July 2026 (effective July 1, 2026). Next CMS release: January 1, 2027 (ASP, MUE, NCCI and OPPS quarterly updates).

Key facts for J7682

Billing unit
300 MG
Tobramycin non-comp unit
ASP payment limit
$11.404
October 2026; -7.3% vs July 2026
Practitioner MUE
2
MAI 3
OPPS status
SI M
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J7682 is the Level II code for Tobramycin, inhalation solution, fda-approved final product, non-compounded,, billed per 300 MG. The Medicare Part B ASP payment limit for October 2026 is $11.404 per billing unit, down 7.3% from July 2026. The practitioner MUE allows up to 2 units per date of service (MAI 3). Under OPPS it carries status indicator M. J7682 is billed in units of 300 MG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. The ASP crosswalk maps 22 NDCs to it, sold as Tobramycin, Tobramycin inhalation, Bethkis by Teva Pharmaceuticals USA, Inc., Chiesi USA, Inc., Northstar RxLLC. No current Billing and Coding Article lists J7682, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J7682 at $11.404 per 300 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $12.305 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J7682
QuarterPayment limitPerCoinsurance
October 2026$11.404300 MG20%
July 2026$12.305300 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 22 NDCs from 15 labelers to J7682. Report the NDC in the claim's drug segment and bill the number of J7682 units that equals the quantity administered divided by 300 MG; the last column gives units per full package.

NDCs that crosswalk to J7682
NDCDrug nameLabelerPackage sizeBilling units / package
00093-3750-28TobramycinTeva Pharmaceuticals USA, Inc.4 × 2828
00093-3750-63TobramycinTeva Pharmaceuticals USA, Inc.4 × 5656
00093-4085-63Tobramycin inhalationTeva Pharmaceuticals USA, Inc.5 × 5656
10122-0820-28BethkisChiesi USA, Inc.4 × 2828
10122-0820-56BethkisChiesi USA, Inc.4 × 5656
16714-0119-03Tobramycin inhalationNorthstar RxLLC5 × 5656
24492-0850-56Kitabis PAKPARI Respiratory Equipment5 × 5656
42571-0408-92Tobramycin inhalationMicro Labs Limited5 × 5656
43598-0605-56Tobramycin inhalationDr. Reddy's Laboratories Inc.5 × 5656
43598-0605-58Tobramycin inhalationDr. Reddy's Laboratories Inc.5 × 5656
47335-0171-49Tobramycin inhalationSun Pharmaceutical Global FZE.5 × 5656
49502-0345-73TobiViatris Specialty LLC5 × 5656
60687-0731-83Tobramycin inhalationAmerican Health Packaging5 × 3030
65162-0914-46Tobramycin inhalationAmneal Pharmaceuticals, LLC5 × 5656
66993-0195-94TobramycinPrasco Laboratories4 × 5656
68180-0962-56Tobramycin inhalationLupin Pharmaceuticals, Inc.5 × 5656
70644-0899-99Tobramycin inhalationGenericus, Inc.5 × 5656
70756-0604-56Tobramycin inhalationLifestar Pharma5 × 5656
70756-0617-56TobramycinLifestar Pharma4 × 5656
72603-0430-56Tobramycin inhalationNorthstar RxLLC5 × 5656
72603-0630-56Tobramycin inhalationNorthstar RxLLC4 × 5656
76204-0029-56Tobramycin inhalationRitedose Pharmaceuticals, LLC5 × 5656

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J7682. For practitioners the limit is 2 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J7682 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services23 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital03 Date of Service Edit: ClinicalCMS Policy
DME supplier1123 Date of Service Edit: ClinicalPrescribing Information

NCCI edits and add-on relationships

No active practitioner PTP pair lists J7682 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

J7682 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J7682 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the July 2026 OPPS Addendum B, J7682 carries status indicator M. Consult the OPPS status indicator table for payment treatment.

Common denials for J7682 and how to prevent them

CARC 16 · M119

NDC missing, invalid or not matched to the HCPCS code

CARC 151 · N362

units billed exceed the MUE for the date of service

CARC 50 · N115

diagnosis not covered by the applicable coverage article or LCD

How QuickIntell checks J7682 before the claim leaves

QuickCode validates the NDC-to-unit conversion against the current ASP crosswalk, checks units against every published MUE setting and flags PTP and add-on conflicts on the same claim. QuickRCM routes CARC 16, 151 and 50 denials on drug lines with the matching coverage article attached so the appeal starts with evidence.

Explore QuickCodeExplore QuickRCMBook a demo

Frequently asked questions — HCPCS J7682

What does HCPCS code J7682 describe?

J7682 is defined by CMS as "Tobramycin, inhalation solution, fda-approved final product, non-compounded,". Each billing unit represents 300 MG, so the units reported on the claim must equal the dose administered divided by that unit.

What is the Medicare reimbursement for J7682 in October 2026?

The ASP-based payment limit is $11.404 per 300 MG, with 20% beneficiary coinsurance. Medicare Administrative Contractors apply this limit; commercial payers use their own fee schedules. The July 2026 limit was $12.305.

How many units of J7682 can be billed per day?

The practitioner Medically Unlikely Edit is 2 units per date of service with adjudication indicator 3 (3 Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J7682?

The October 2026 ASP crosswalk lists 22 NDCs from 15 labelers: Tobramycin (Teva Pharmaceuticals USA, Inc.); Tobramycin inhalation (Teva Pharmaceuticals USA, Inc.); Bethkis (Chiesi USA, Inc.); Tobramycin inhalation (Northstar RxLLC). For example NDC 00093-3750-28 is a 4 package equal to 28 billing units. The crosswalk's billing-units-per-package figure converts each package into J7682 units.

Does J7682 have NCCI bundling edits?

No active practitioner PTP pairs list J7682 as a column-1 or column-2 code in the v323r0 release. Unit limits (MUE) and medical-necessity coverage rules still apply.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-01. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B and the Medicare Coverage Database. Payment limits are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.